Firma Immunic, Autor bei Presse-Blog

Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

3. August 2020 Firma ImmunicForschung und Entwicklung4sc, altium, brain, fiscal, immunic, immunic's, imu, liver, market, patients, revenue, rrms, statements, syndrome, with

Study Meets Primary and Key Secondary Endpoints with High Statistical Significance Indicating Activity for IMU-838 in Relapsing-Remitting Multiple Sclerosis Statistically Significant Reduction of 62% and 70% in Combined Unique Active Magnetic Resonance Imaging Lesions in 45mg and 30mg Patient Cohorts, Mehr

Immunic, Inc. Announces First Patients Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of IMU-838 in Combination with Oseltamivir for the Treatment of Patients with Moderate-to-Severe COVID-19

27. Juli 202013. Dezember 2023 Firma ImmunicAllgemeincancer, dosing, fiscal, immunic, immunic's, imu, market, nhs, patients, revenue, securities, statements, syndrome, ulcerative, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced enrollment of the first patients in an investigator-sponsored phase 2 clinical trial of the company’s selective Mehr

Immunic, Inc. to Join Russell 3000® Index

22. Juni 202013. Dezember 2023 Firma ImmunicForschung und Entwicklungcolitis, cov, covid, fiscal, immunic, immunic's, imu, index??, market, revenue, securities, statements, syndrome, ulcerative, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that the company is set to join the broad-market Russell 3000® Index at the conclusion of the Mehr

Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

15. Juni 2020 Firma ImmunicForschung und Entwicklungcalvid, colitis, dosing, fiscal, immunic, immunic's, imu, market, patients, revenue, securities, statements, syndrome, ulcerative, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced dosing of the first patients in its phase 2, CALVID-1 clinical trial of IMU-838, the Mehr

Immunic, Inc. Announces Proposed Public Offering of Common Stock

10. Juni 2020 Firma ImmunicFirmeninternclinical, covid, fiscal, immunic, immunic's, imu, market, prospectus, revenue, roth, securities, statements, syndrome, treatment, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced it has commenced a public offering of shares of its common stock. Immunic intends to use Mehr

Immunic, Inc. Announces U.S. Food and Drug Administration Allowance of its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

9. Juni 202013. Dezember 2023 Firma ImmunicForschung und Entwicklungcalvid, cells, colitis, fiscal, immunic, immunic's, imu, market, patients, revenue, securities, statements, syndrome, ulcerative, with

Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced receipt of regulatory allowance from the U.S. Food and Drug Administration (FDA) to initiate its phase Mehr

Immunic, Inc. to Host Virtual R&D Day Today, May 19, 2020

19. Mai 202013. Dezember 2023 Firma ImmunicAllgemeindosing, fever, fiscal, hcmv, hella, immunic, immunic's, imu, market, patients, revenue, securities, statements, syndrome, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that it will host a virtual R&D Day today, May 19, 2020, from 9:00 am to 1:00 Mehr

Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients

14. Mai 202013. Dezember 2023 Firma ImmunicBiotechnikcell, colitis, dosing, fiscal, immunic, immunic's, imu, market, patients, revenue, securities, statements, syndrome, ulcerative, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that it has received first regulatory approval from Germany’s BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) to Mehr

Immunic, Inc. Announces Pricing of $15 Million Financing

23. April 2020 Firma ImmunicForschung und Entwicklungaltium, clinical, fiscal, immunic, immunic's, imu, market, prospectus, revenue, roth, securities, statements, syndrome, treatment, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that it has entered into securities purchase agreements with certain institutional investors, led by Altium Capital, Mehr

Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients

22. April 202013. Dezember 2023 Firma ImmunicAllgemeindosing, est, hcmv, hella, immunic, immunic's, imu, market, patients, revenue, statements, syndrome, ulcerative, vaccines, with

. – In Cellular Assays with SARS-CoV-2 Clinical Isolates, IMU-838 Shows Ability to Inhibit Viral Replication of SARS-CoV-2 – Live Webcast will be Held at 8:00am EST / 5:00am PST / 2:00pm CEST on Wednesday, April 22, 2020 Immunic, Inc. Mehr

Autor: Firma Immunic